Bronchiectasis: Causes, Symptoms, and Treatment

Bronchiectasis is a condition characterized by permanent and irreversible dilatations of the bronchial walls. It can be caused by various factors, including cystic fibrosis, immune system deficiencies, lung infections, foreign body aspiration, and smoking. Common symptoms of bronchiectasis include high sputum production, recurrent chest infections, and frequent but usually not severe haemoptysis. Patients may also experience postnasal drip, chronic sinusitis, and undue tiredness. A high-resolution computed tomography (HR-CT) scan is usually used to diagnose bronchiectasis. Treatment involves a multidisciplinary approach, including chest physiotherapy, patient education on airway-clearing techniques, antibiotic treatment during infective exacerbations, and bronchodilators in case of airflow obstruction. While treatment of the underlying cause may be necessary, it does not provide reversal of the existing bronchiectasis. Other conditions, such as sarcoidosis, fibrosing alveolitis, lung cancer, and asthma, are unlikely to produce the same clinical picture as bronchiectasis.

The treatment for Pneumocystis jiroveci pneumonia involves the use of co-trimoxazole, a combination of trimethoprim and sulfamethoxazole.

Pneumocystis jiroveci Pneumonia in HIV Patients

Pneumocystis jiroveci pneumonia (formerly known as Pneumocystis carinii pneumonia) is a common opportunistic infection in individuals with AIDS. Pneumocystis jiroveci is an organism that is classified as a fungus by some and a protozoa by others. Patients with a CD4 count below 200/mm³ should receive prophylaxis for PCP. Symptoms of PCP include dyspnea, dry cough, fever, and few chest signs. Pneumothorax is a common complication of PCP, and extrapulmonary manifestations are rare.

Chest X-rays typically show bilateral interstitial pulmonary infiltrates, but other findings such as lobar consolidation may also be present. Sputum tests often fail to show PCP, and bronchoalveolar lavage (BAL) is often necessary to demonstrate the presence of the organism. Treatment for PCP includes co-trimoxazole and IV pentamidine in severe cases. Aerosolized pentamidine is an alternative treatment but is less effective and carries a risk of pneumothorax. Steroids may be used if the patient is hypoxic, as they can reduce the risk of respiratory failure and death.

In summary, PCP is a common opportunistic infection in individuals with AIDS, and prophylaxis should be given to those with a CD4 count below 200/mm³. Symptoms include dyspnea, dry cough, and fever, and chest X-rays typically show bilateral interstitial pulmonary infiltrates. Treatment includes co-trimoxazole, IV pentamidine, and steroids if the patient is hypoxic.

Rhinoviruses are responsible for causing the common cold, while respiratory syncytial virus is a common cause of bronchiolitis. Influenza virus is the culprit behind the flu, while Streptococcus pneumonia is the most frequent cause of community-acquired pneumonia. Parainfluenza virus is commonly associated with croup.

Respiratory Pathogens and Their Associated Conditions

Respiratory pathogens are microorganisms that cause infections in the respiratory system. The most common respiratory pathogens include respiratory syncytial virus, parainfluenza virus, rhinovirus, influenza virus, Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Mycoplasma pneumoniae, Legionella pneumophilia, and Pneumocystis jiroveci. Each of these pathogens is associated with a specific respiratory condition.

Respiratory syncytial virus is known to cause bronchiolitis, while parainfluenza virus is associated with croup. Rhinovirus is the most common cause of the common cold, while influenza virus causes the flu. Streptococcus pneumoniae is the most common cause of community-acquired pneumonia, and Haemophilus influenzae is the most common cause of bronchiectasis exacerbations and acute epiglottitis. Staphylococcus aureus is known to cause pneumonia, particularly following influenza. Mycoplasma pneumoniae causes atypical pneumonia, which is characterized by flu-like symptoms that precede a dry cough. Legionella pneumophilia is another cause of atypical pneumonia, which is typically spread by air-conditioning systems and causes a dry cough. Pneumocystis jiroveci is a common cause of pneumonia in HIV patients, and patients typically have few chest signs and develop exertional dyspnea. Mycobacterium tuberculosis causes tuberculosis, which can present in a wide range of ways, from asymptomatic to disseminated disease. Cough, night sweats, and weight loss may be seen in patients with tuberculosis.

Pneumonia is a serious respiratory infection that requires prompt assessment and management. In the primary care setting, the CRB65 criteria are used to stratify patients based on their risk of mortality. Patients with a score of 0 are considered low risk and may be treated at home, while those with a score of 3 or 4 are high risk and require urgent admission to hospital. The use of a point-of-care CRP test can help guide antibiotic therapy. In the secondary care setting, the CURB65 criteria are used, which includes an additional criterion of urea > 7 mmol/L. Chest x-rays and blood and sputum cultures are recommended for intermediate or high-risk patients. Treatment for low-severity community acquired pneumonia typically involves a 5-day course of amoxicillin, while moderate and high-severity cases may require dual antibiotic therapy for 7-10 days. Discharge criteria and advice post-discharge are also provided, including information on expected symptom resolution timeframes and the need for a repeat chest x-ray at 6 weeks.

To prevent angina attacks, the first-line treatment is either a beta-blocker or a calcium channel blocker. This patient is displaying symptoms of stable angina, which includes shortness of breath and chest tightness that occurs during exercise and is relieved by rest. The ECG results are normal, ruling out any serious conditions like myocardial infarction. According to NICE guidelines, all patients with stable angina should receive aspirin and a statin, unless there are contraindications. Additionally, sublingual glyceryl trinitrate spray (GTN) should be given to stop acute angina attacks. However, GTN spray does not prevent future attacks, so prophylactic medication should also be prescribed.

Angina pectoris is a condition that can be managed through various methods, including lifestyle changes, medication, percutaneous coronary intervention, and surgery. In 2011, NICE released guidelines for the management of stable angina. Medication is an important aspect of treatment, and all patients should receive aspirin and a statin unless there are contraindications. Sublingual glyceryl trinitrate can be used to abort angina attacks. The first-line medication should be either a beta-blocker or a calcium channel blocker, depending on the patient’s comorbidities, contraindications, and preferences. If a calcium channel blocker is used as monotherapy, a rate-limiting one such as verapamil or diltiazem should be used. If used in combination with a beta-blocker, a longer-acting dihydropyridine calcium channel blocker should be used. Beta-blockers should not be prescribed concurrently with verapamil due to the risk of complete heart block. If the initial treatment is not effective, medication should be increased to the maximum tolerated dose. If a patient is still symptomatic after monotherapy with a beta-blocker, a calcium channel blocker can be added, and vice versa. If a patient cannot tolerate the addition of a calcium channel blocker or a beta-blocker, other drugs such as long-acting nitrates, ivabradine, nicorandil, or ranolazine can be considered. Nitrate tolerance is a common issue, and patients who take standard-release isosorbide mononitrate should use an asymmetric dosing interval to maintain a daily nitrate-free time of 10-14 hours to minimize the development of nitrate tolerance. This effect is not seen in patients who take once-daily modified-release isosorbide mononitrate. If a patient is taking both a beta-blocker and a calcium-channel blocker, a third drug should only be added while awaiting assessment for PCI or CABG.

This patient is at a high risk of having a PE, scoring 7 points on her Wells’ score and presenting with a typical history of PE, along with several risk factors such as immobilisation and being on the COCP. Ideally, a CT pulmonary angiogram would be performed, but a contrast allergy is an absolute contraindication. Giving fluids or hydrocortisone and chlorphenamine would not reduce the risk of contrast allergy. A CT chest without contrast is not diagnostic for a PE. In such cases, a V/Q scan is the best option, but it may not be available out of hours. Therefore, given the strong suspicion of a PE, the patient should be started on treatment dose anticoagulation while awaiting the scan. NICE recommends using DOACs like apixaban as interim therapeutic anticoagulation. It is important to note that prophylactic heparin is used to prevent a PE, not to treat a PE.

Investigating Pulmonary Embolism: Key Features and Diagnostic Criteria

Pulmonary embolism (PE) can be challenging to diagnose as it can present with a wide range of cardiorespiratory symptoms and signs depending on its location and size. The PIOPED study in 2007 found that tachypnea, crackles, tachycardia, and fever were the most common clinical signs associated with PE. To aid in the diagnosis of PE, NICE updated their guidelines in 2020 to include the use of the pulmonary embolism rule-out criteria (PERC) and the 2-level PE Wells score. The PERC rule should be used when there is a low pre-test probability of PE, and a negative PERC result reduces the probability of PE to less than 2%. The 2-level PE Wells score should be performed if a PE is suspected, with a score of more than 4 points indicating a likely PE and a score of 4 points or less indicating an unlikely PE.

If a PE is likely, an immediate computed tomography pulmonary angiogram (CTPA) should be arranged, and interim therapeutic anticoagulation should be given if there is a delay in getting the CTPA. If a PE is unlikely, a D-dimer test should be arranged, and if positive, an immediate CTPA should be performed. The consensus view from the British Thoracic Society and NICE guidelines is that CTPA is the recommended initial lung-imaging modality for non-massive PE. However, V/Q scanning may be used initially if appropriate facilities exist, the chest x-ray is normal, and there is no significant symptomatic concurrent cardiopulmonary disease.

Other diagnostic tools include age-adjusted D-dimer levels, ECG, chest x-ray, V/Q scan, and CTPA. It is important to note that a chest x-ray is recommended for all patients to exclude other pathology, but it is typically normal in PE. While investigating PE, it is crucial to consider other differential diagnoses and to tailor the diagnostic approach to the individual patient’s clinical presentation and risk factors.

The National Institute for Clinical Excellence (NICE) recommends that patients suspected of having an exacerbation of COPD undergo several tests, including arterial blood gases, chest X-ray, electrocardiogram, full blood count and urea and electrolytes, and theophylline level (if applicable). Sputum microscopy and culture should also be done if the sputum is purulent, and blood cultures if the patient has a fever. Medical therapy should include oxygen to maintain the patient within their individualized target range, nebulized bronchodilators, steroid therapy, antibiotics if necessary, and chest physiotherapy. If the patient does not respond well to nebulized bronchodilators, intravenous theophyllines may be considered. For patients with persistent hypercapnic ventilatory failure despite optimal medical therapy, non-invasive ventilation should be considered. In this case, a trial of BIPAP would be the best option since intravenous theophylline is not available. BIPAP is a form of non-invasive ventilation that has been proven effective in acute type two respiratory failure. It works by stenting alveoli open to increase the surface area available for ventilation and gas exchange. CPAP is another form of non-invasive ventilation but is not as effective as BIPAP in COPD. Intubation and ventilation may be necessary in some patients with COPD, but a trial of non-invasive ventilation is the most appropriate next step. It is important to set a ceiling of care for all patients presenting with an exacerbation of COPD. Regular arterial blood gas analysis is necessary to assess the patient’s response to NIV.

Acute exacerbations of COPD are a common reason for hospital visits in developed countries. The most common causes of these exacerbations are bacterial infections, with Haemophilus influenzae being the most common culprit, followed by Streptococcus pneumoniae and Moraxella catarrhalis. Respiratory viruses also account for around 30% of exacerbations, with human rhinovirus being the most important pathogen. Symptoms of an exacerbation include an increase in dyspnea, cough, and wheezing, as well as hypoxia and acute confusion in some cases.

NICE guidelines recommend increasing the frequency of bronchodilator use and giving prednisolone for five days. Antibiotics should only be given if sputum is purulent or there are clinical signs of pneumonia. Admission to the hospital is recommended for patients with severe breathlessness, acute confusion or impaired consciousness, cyanosis, oxygen saturation less than 90%, social reasons, or significant comorbidity.

For severe exacerbations requiring secondary care, oxygen therapy should be used with an initial saturation target of 88-92%. Nebulized bronchodilators such as salbutamol and ipratropium should also be administered, along with steroid therapy. IV hydrocortisone may be considered instead of oral prednisolone, and IV theophylline may be used for patients not responding to nebulized bronchodilators. Non-invasive ventilation may be used for patients with type 2 respiratory failure, with bilevel positive airway pressure being the typical method used.

For an adult with asthma that is not controlled by a short-acting beta-agonist, the appropriate next step is to add a low-dose inhaled corticosteroid. This is in accordance with NICE guidelines. The addition of a combined inhaled corticosteroid and long-acting beta-agonist is not recommended until symptoms cannot be controlled with a low-dose inhaled corticosteroid and a short-acting beta-agonist, with or without a leukotriene receptor antagonist. Similarly, a leukotriene receptor antagonist or long-acting beta-agonist should not be introduced until symptoms are not controlled with a low-dose inhaled corticosteroid and a short-acting beta-agonist, with or without a leukotriene receptor antagonist.

The management of asthma in adults has been updated by NICE in 2017, following the 2016 BTS guidelines. One of the significant changes is in ‘step 3’, where patients on a SABA + ICS whose asthma is not well controlled should be offered a leukotriene receptor antagonist instead of a LABA. NICE does not follow the stepwise approach of the previous BTS guidelines, but to make the guidelines easier to follow, we have added our own steps. The steps range from newly-diagnosed asthma to SABA +/- LTRA + one of the following options, including increasing ICS to high-dose, a trial of an additional drug, or seeking advice from a healthcare professional with expertise in asthma. Maintenance and reliever therapy (MART) is a form of combined ICS and LABA treatment that is only available for ICS and LABA combinations in which the LABA has a fast-acting component. It should be noted that NICE does not recommend changing treatment in patients who have well-controlled asthma simply to adhere to the latest guidance. The definitions of what constitutes a low, moderate, or high-dose ICS have also changed, with <= 400 micrograms budesonide or equivalent being a low dose, 400 micrograms - 800 micrograms budesonide or equivalent being a moderate dose, and > 800 micrograms budesonide or equivalent being a high dose for adults.

Correct and Incorrect Treatment Approaches for Acute Asthma Exacerbation in Children

Acute asthma exacerbation in children requires prompt and appropriate treatment to prevent complications. Here are some correct and incorrect treatment approaches for this condition:

Course of oral steroids: Giving oral steroids early in the treatment of acute asthma attacks in children is advisable. The initial course length should be tailored to response.

Wean down salbutamol to 2 puffs twice a day before hospital discharge: Weaning down salbutamol to two puffs twice a day before hospital discharge is incorrect. Children may be discharged from hospital once stable on 3- to 4-hourly bronchodilators which can be continued at home.

Addition of salmeterol inhaler: Adding a salmeterol inhaler is incorrect. The initial next step of treatment should be inhaled corticosteroids (ICSs) for patients who have had an asthma attack in the last two years.

Continue monitoring in hospital until salbutamol is no longer required: Continuing monitoring in hospital until salbutamol is no longer required is incorrect. Children may be discharged from hospital once stable on 3- to 4-hourly bronchodilators which can be continued at home.

IV hydrocortisone: Administering IV hydrocortisone is incorrect. It is reserved for the treatment of acute life-threatening asthma.

Arterial Blood Gas Interpretation Made Easy

Arterial blood gas interpretation can be a daunting task for healthcare professionals. However, the Resuscitation Council (UK) has provided a simple 5-step approach to make it easier. The first step is to assess the patient’s overall condition. The second step is to determine if the patient is hypoxaemic, which is indicated by a PaO2 level of less than 10 kPa on air. The third step is to check if the patient is acidaemic or alkalaemic, which is determined by the pH level. A pH level of less than 7.35 indicates acidaemia, while a pH level of more than 7.45 indicates alkalaemia.

The fourth step is to assess the respiratory component by checking the PaCO2 level. A PaCO2 level of more than 6.0 kPa suggests respiratory acidosis, while a PaCO2 level of less than 4.7 kPa suggests respiratory alkalosis. The fifth and final step is to evaluate the metabolic component by checking the bicarbonate level or base excess. A bicarbonate level of less than 22 mmol/l or a base excess of less than -2mmol/l indicates metabolic acidosis, while a bicarbonate level of more than 26 mmol/l or a base excess of more than +2mmol/l indicates metabolic alkalosis.

To make it easier to remember, healthcare professionals can use the ROME acronym. Respiratory is opposite, which means that low pH and high PaCO2 indicate acidosis, while high pH and low PaCO2 indicate alkalosis. Metabolic is equal, which means that low pH and low bicarbonate indicate acidosis, while high pH and high bicarbonate indicate alkalosis. By following this simple approach, healthcare professionals can easily interpret arterial blood gas results and provide appropriate treatment for their patients.